Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
McKinsey
Cipla
Baxter
Farmers Insurance
Merck
Johnson and Johnson
Boehringer Ingelheim
QuintilesIMS

Generated: April 20, 2018

DrugPatentWatch Database Preview

Viiv Hlthcare Company Profile

« Back to Dashboard

Summary for Viiv Hlthcare
International Patents:863
US Patents:17
Tradenames:12
Ingredients:12
NDAs:19

Drugs and US Patents for Viiv Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare LEXIVA fosamprenavir calcium SUSPENSION;ORAL 022116-001 Jun 14, 2007 RX Yes Yes 6,436,989*PED ➤ Sign Up ➤ Sign Up
Viiv Hlthcare TIVICAY dolutegravir sodium TABLET;ORAL 204790-002 Jun 9, 2016 RX Yes No ➤ Sign Up ➤ Sign Up
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-004 Nov 4, 2016 RX Yes No 7,368,460 ➤ Sign Up ➤ Sign Up
Viiv Hlthcare TIVICAY dolutegravir sodium TABLET;ORAL 204790-003 Jun 9, 2016 RX Yes No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Viiv Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare RETROVIR zidovudine TABLET;ORAL 020518-002 Oct 4, 1996 4,828,838 ➤ Sign Up
Viiv Hlthcare RETROVIR zidovudine CAPSULE;ORAL 019655-001 Mar 19, 1987 4,828,838 ➤ Sign Up
Viiv Hlthcare RETROVIR zidovudine TABLET;ORAL 020518-001 Dec 19, 1995 4,833,130 ➤ Sign Up
Viiv Hlthcare RETROVIR zidovudine CAPSULE;ORAL 019655-001 Mar 19, 1987 4,833,130 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for VIIV HLTHCARE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 300 mg ➤ Subscribe 2009-01-28
➤ Subscribe Tablets 150 mg and 300 mg ➤ Subscribe 2007-10-16
➤ Subscribe Tablets 300 mg/150 mg/300 mg ➤ Subscribe 2011-03-22
➤ Subscribe Oral Solution 10 mg/mL ➤ Subscribe 2011-11-22
➤ Subscribe Tablets 10 mg, 25 mg and 50 mg ➤ Subscribe 2017-08-14
➤ Subscribe Tablets 600 mg/50 mg/300 mg ➤ Subscribe 2017-08-14
➤ Subscribe Tablets 600 mg/300 mg ➤ Subscribe 2007-09-27
➤ Subscribe Tablets 150 mg/300 mg ➤ Subscribe 2007-06-26
➤ Subscribe Tablets 150 mg and 300 mg ➤ Subscribe 2011-08-08
➤ Subscribe Tablets 700 mg ➤ Subscribe 2012-01-18
➤ Subscribe Oral Solution 20 mg/ml ➤ Subscribe 2012-12-27

Non-Orange Book US Patents for Viiv Hlthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,838,474 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors ➤ Sign Up
7,592,368 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors ➤ Sign Up
6,503,905 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives ➤ Sign Up
7,108,864 Tablet formation ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Viiv Hlthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016000110 Germany ➤ Sign Up PRODUCT NAME: KOMBINATION VON RILPIVIRINHYDROCHLORID ODER EINER THERAPEUTISCH AEQUIVALENTEN, DURCH DAS GRUNDPATENT GESCHUETZTEN FORM DAVON UND TENOFOVIRALAFENAMID ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/16/1112 20160621
0120010 00057 Estonia ➤ Sign Up PRODUCT NAME: EDURANT - RILPIVIRIIN;REG NO/DATE: C(2011)8955 FINAL 28.11.2011
00195 Netherlands ➤ Sign Up PRODUCT NAME: ABACAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDB AAR ZUURADDITIEZOUT, IN HET BIJZONDER HET HEMISULFAAT, EN LAMIV UDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT; REGISTRTION NO/DATE: EU/04/298/001-002 20041217
0676 Netherlands ➤ Sign Up PRODUCT NAME: DOLUTEGRAVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN, MET INBEGRIP VAN DOLUTEGRAVIR NATRIUM; REGISTRATION NO/DATE: EU/1/13/892 20140121
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Teva
US Department of Justice
Merck
Healthtrust
Medtronic
McKesson
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.